Positron emission tomography image-guided drug delivery: Current status and future perspectives

Molecular Pharmaceutics

Volumn 11, Issue 11, 2014, Pages 3777-3797

  Chakravarty, Rubel ^a,b   Hong, Hao ^a   Cai, Weibo ^a,c,d  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b BHABHA ATOMIC RESEARCH CENTRE   (India)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Cancer; Image guided drug delivery; Molecular imaging personalized medicine; Positron emission tomography; Theranostics

Indexed keywords

ALBUMIN; CARBON NANOPARTICLE; DRUG CARRIER; LIPOSOME; METAL NANOPARTICLE; NANOPARTICLE; OXIDE NANOPARTICLE; POLYMER; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CARBON; MICELLE; OXIDE;

CANCER DIAGNOSIS; CANCER PATIENT; CANCER THERAPY; CONTROLLED DRUG RELEASE; DRUG DELIVERY SYSTEM; ENZYME PRODRUG THERAPY; HUMAN; MICELLE; MOLECULAR IMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; ANIMAL; CHEMISTRY; MOUSE; NANOMEDICINE; PERSONALIZED MEDICINE; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; CARBON; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; MICE; MICELLES; NANOMEDICINE; NANOPARTICLES; OXIDES; POLYMERS; POSITRON-EMISSION TOMOGRAPHY; PRECISION MEDICINE;

EID: 84965188036     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp500173s     Document Type: Review

References (227)

1. Hatefi, A.; Minko, T. Advances in image-guided drug delivery. Drug Delivery Transl. Res. 2012, 2, 1-2.
2. Gaidamakova, E. K.; Backer, M. V.; Backer, J. M. Molecular vehicle for target-mediated delivery of therapeutics and diagnostics. J. Controlled Release 2001, 74, 341-7.
3. MacKay, J. A.; Li, Z. Theranostic agents that co-deliver therapeutic and imaging agents? Adv. Drug Delivery Rev. 2010, 62, 1003-4.
4. Chow, E. K.; Ho, D. Cancer nanomedicine: from drug delivery to imaging. Sci. Transl. Med. 2013, 5, 216rv4.
5. Solorio, L.; Patel, R B.; Wu, H.; Krupka, T.; Exner, A. A. Advances in image-guided intratumoral drug delivery techniques. Ther. Delivery 2010, 1, 307-22.
6. Fass, L. Imaging and cancer: a review. Mol. Oncol. 2008, 2, 115-52.
7. Arias, J. L. Advanced methodologies to formulate nanotheragnostic agents for combined drug delivery and imaging. Expert Opin. Drug Delivery 2011, 8, 1589-608.
8. Iyer, A K.; He, J.; Amiji, M. M. Image-guided nanosystems for targeted delivery in cancer therapy. Curr. Med. Chem. 2012, 19, 3230-40.
9. Terreno, E.; Uggeri, F.; Ame, S. Image guided therapy: the advent of theranostic agents. J. Controlled Release 2012, 161, 328-37.
10. Zhang, Y.; Chan, H. F.; Leong, K. W. Advanced materials and processing for drug delivery: the past and the future. Adv. Drug Delivery Rev. 2013, 65, 104-20.
11. Viness, P.; Pradeep, K.; Yahya, E. C. Cutting-edge techniques for molecular imaging with relevance to therapeutic delivery methods. In Therapeutic Delivery Methods: A Concise Overview of Emerging Areas; Future Science Ltd: London, 2013; pp 126-144.
12. Bao, G.; Mitragotri, S.; Tong, S. Multifunctional nanoparticles for drug delivery and molecular imaging. Annu. Rev. Biomed. Eng. 2013, 15, 253-82.
13. Malviya, G.; Nayak, T. K. PET Imaging to Monitor Cancer Therapy. Curr. Pharm. Biotechnol. 2013, 14, 669-82.
14. Herschman, H. R Molecular imaging: looking at problems, seeing solutions. Science 2003, 302, 605-8.
15. Weissleder, R; Pittet, M. J. Imaging in the era of molecular oncology. Nature 2008, 452, 580-9.
16. Hoffman, J. M.; Gambhir, S. S. Molecular imaging: the vision and opportunity for radiology in the future. Radiology 2007, 244, 39-47.
17. Berry, C. R; Garg, P. Perspectives in molecular imaging through translational research, human medicine, and veterinary medicine. Semin. Nucl. Med. 2014, 44, 66-75.
18. Jokerst, J. V.; Gambhir, S. S. Molecular imaging with theranostic nanoparticles. Acc. Chem. Res. 2011, 44, 1050-60.
19. Ametamey, S. M.; Honer, M.; Schubiger, P. A. Molecular imaging with PET. Chem. Rev. 2008, 108, 1501-16.
20. Jennings, L. E.; Long, N. J. 'Two is better than one'-probes for dual-modality molecular imaging. Chem. Commun. 2009, 3511-24.
21. Kiessling, F.; Fokong, S.; Bzyl, J.; Lederle, W.; Palmowski, M.; Lammers, T. Recent advances in molecular, multimodal and theranostic ultrasound imaging. Adv. Drug Delivery Rev. 2014, 72, 15-27, DOI: 10.1016/j.addr.2013.11.013.
22. Song, Y.; Huang, Z.; Xu, J.; Ren, D.; Wang, Y.; Zheng, X.; Shen, Y.; Wang, L.; Gao, H; Hou, J.; Pang, Z.; Qian, J.; Ge, J. Multimodal SPION-CREKA peptide based agents for molecular imaging of microthrombus in a rat myocardial ischemia-reperfusion model. Biomaterials 2014, 35, 2961-2970.
23. Thorek, D. L.; Ulmert, D.; Diop, N. F.; Lupu, M. E.; Doran, M. G; Huang, R; Abou, D. S.; Larson, S. M.; Grimm, J. Non-invasive mapping of deep-tissue lymph nodes in live animals using a multimodal PET/MRI nanoparticle. Nat. Commun. 2014, 5, 3097.
24. Basu, S. Personalized versus evidence-based medicine with PET-based imaging. Nat. Rev. Clin. Oncol. 2010, 7, 665-8.
25. Bussink, J.; Kaanders, J. H; van der Graaf, W. T.; Oyen, W. J. PET-CT for radiotherapy treatment planning and response monitoring in solid tumors. Nat. Rev. Clin. Oncol. 2011, 8, 233-42.
26. Gambhir, S. S. Molecular imaging of cancer with positron emission tomography. Nat. Rev. Cancer 2002, 2, 683-93.
27. Hicks, R J.; Hofman, M. S. Is there still a role for SPECT-CT in oncology in the PET-CT era? Nat. Rev. Clin. Oncol. 2012, 9, 712-20.
28. Cunha, L.; Szigeti, K.; Mathe, D.; Metello, L. F. The role of molecular imaging in modern drug development. Drug Discovery Today 2014, DOI: 10.1016/j.drudis.2014.01.003, Epub ahead of print.
29. Heskamp, S.; van Laarhoven, H. W.; van der Graaf, W. T.; Oyen, W. J.; Boerman, O. C. Radionuclide imaging of drug delivery for patient selection in targeted therapy. Expert Opin. Drug Delivery 2014, 11, 175-85.
30. Jang, B. S. MicroSPECT and MicroPET Imaging of Small Animals for Drug Development. Toxicol. Res. 2013, 29, 1-6.
31. Sharma, P.; Singh, H.; Basu, S.; Kumar, R. Positron emission tomography-computed tomography in the management of lung cancer: An update. South Asian J. Cancer 2013, 2, 171-8.
32. 11C]docetaxel. Front. Oncol. 2013, 3, 208.
33. Lankveld, D. P.; Rayavarapu, R. G.; Krystek, P.; Oomen, A. G.; Verharen, H. W.; van Leeuwen, T. G.; De Jong, W. H.; Manohar, S. Blood clearance and tissue distribution of PEGylated and non-PEGylated gold nanorods after intravenous administration in rats. Nanomedicine (London) 2011, 6, 339-49.
34. Larsen, E. K.; Nielsen, T.; Wittenborn, T.; Rydtoft, L. M.; Lokanathan, A. R.; Hansen, L.; Ostergaard, L.; Kingshott, P.; Howard, K. A.; Besenbacher, F.; Nielsen, N. C.; Kjems, J. Accumulation of magnetic iron oxide nanoparticles coated with variably sized polyethylene glycol in murine tumors. Nanoscale 2012, 4, 2352-61.
35. Ohno, K.; Akashi, T.; Tsujii, Y.; Yamamoto, M.; Tabata, Y. Blood clearance and biodistribution of polymer brush-afforded silica particles prepared by surface-initiated living radical polymerization. Biomacromolecules 2012, 13, 927-36.
36. Zhao, X.; Zhao, H.; Chen, Z.; Lan, M. Ultrasmall superparamagnetic iron oxide nanoparticles for magnetic resonance imaging contrast agent. J. Nanosci. Nanotechnol. 2014, 14, 210-20.
37. Dong, H.; Dube, N.; Shu, J. Y.; Seo, J. W.; Mahakian, L. M.; Ferrara, K. W.; Xu, T. Long-circulating 15 nm micelles based on amphiphilic 3-helix peptide-PEG conjugates. ACS Nano 2012, 6, 5320-9.
38. Gabizon, A.; Papahadjopoulos, D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc. Natl. Acad. Sci. U. S. A. 1988, 85, 6949-53.
39. Liu, X.; Tao, H.; Yang, K.; Zhang, S.; Lee, S. T.; Liu, Z. Optimization of surface chemistry on single-walled carbon nanotubes for in vivo photothermal ablation of tumors. Biomaterials 2011, 32, 144-51.
40. Lammers, T.; Kiessling, F.; Hennink, W. E.; Storm, G. Nanotheranostics and image-guided drug delivery: current concepts and future directions. Mol. Pharmaceutics 2010, 7, 1899-912.
41. Janib, S. M.; Moses, A. S.; MacKay, J. A. Imaging and drug delivery using theranostic nanoparticles. Adv. Drug Delivery Rev. 2010, 62, 1052-63.
42. Wilbur, D. S.; Pathare, P. M.; Hamlin, D. K.; Stayton, P. S.; To, R.; Klumb, L. A.; Buhler, K. R.; Vessella, R. L. Development of new biotin/streptavidin reagents for pretargeting. Biomol. Eng. 1999, 16, 113-8.
43. Pene, F.; Courtine, E.; Cariou, A.; Mira, J. P. Toward theragnostics. Crit. Care Med. 2009, 37, S50-8.
44. Liu, S. Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides. Adv. Drug Delivery Rev. 2008, 60, 1347-70.
45. Bertrand, N.; Wu, J.; Xu, X.; Kamaly, N.; Farokhzad, O. C. Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology. Adv. Drug Delivery Rev. 2014, 66, 2-25.
46. 90Y-microspheres. J. Nucl. Med. 2013, 54, 516-22.
47. Elzoghby, A. O.; Samy, W. M.; Elgindy, N. A. Albumin-based nanoparticles as potential controlled release drug delivery systems. J. Controlled Release 2012, 157, 168-82.
48. Misak, H. E.; Asmatulu, R.; Gopu, J. S.; Man, K. P.; Zacharias, N. M.; Wooley, P. H.; Yang, S. Y. Albumin-Based Nanocomposite Spheres for Advanced Drug Delivery Systems. Biotechnol. J. 2014, 9, 163-70.
49. Wu, Y.; Ihme, S.; Feuring-Buske, M.; Kuan, S. L.; Eisele, K.; Lamla, M.; Wang, Y.; Buske, C; Weil, T. A core-shell albumin copolymer nanotransporter for high capacity loading and two-step release of doxorubicin with enhanced anti-leukemia activity. Adv. Healthcare Mater. 2013, 2, 884-94.
50. 8Ga-MAA. Int. J. Radiat. Appl. Instrum. B 1989, 16, 319-21.
51. Okada, S.; Ohto, M.; Kuniyasu, Y.; Higashi, S.; Arimizu, N.; Uematsu, S. Estimation of the reticuloendothelial function by positron emission computed tomography (PET) study in chronic liver disease. Nihon Shokakibyo Gakkai Zasshi 1990, 87, 90-9.
52. 99mTc-MAA microspheres. Appl. Radiat. Isot. 2011, 69, 171-5.
53. Geschwind, J. F.; Salem, R.; Carr, B. I.; Soulen, M. C.; Thurston, K. G; Goin, K. A.; Van Buskirk, M.; Roberts, C. A.; Goin, J. E. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 2004, 127, S194-205.
54. Kennedy, A. S.; Salem, R. Radioembolization (yttrium-90 microspheres) for primary and metastatic hepatic malignancies. Cancer J. 2010, 16, 163-75.
55. Murthy, R; Nunez, R; Szklaruk, J.; Erwin, W.; Madoff, D. C.; Gupta, S.; Ahrar, K; Wallace, M. J.; Cohen, A; Coldwell, D. M.; Kennedy, A. S.; Hicks, M. E. Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics 2005, 25(Suppl. 1), S41-55.
56. Liao, A H.; Wu, S. Y.; Wang, H. E.; Weng, C. H.; Wu, M. F.; Li, P. C. Evaluation of F-labeled targeted perfluorocarbon-filled albumin microbubbles as a probe for microUS and microPET in tumor-bearing mice. Ultrasonics 2013, 53, 320-7.
57. Goyal, P.; Goyal, K; Vijaya Kumar, S. G; Singh, A; Katare, O. P.; Mishra, D. N. Liposomal drug delivery systems-clinical applications. Acta Pharm. 2005, 55, 1-25.
58. Medina, O. P.; Zhu, Y.; Kairemo, K. Targeted liposomal drug delivery in cancer. Curr. Pharm. Des 2004, 10, 2981-9.
59. Petersen, A L.; Hansen, A E.; Gabizon, A.; Andresen, T. L. Liposome imaging agents in personalized medicine. Adv. Drug Delivery Rev. 2012, 64, 1417-35.
60. Klibanov, A. L.; Maruyama, K; Torchilin, V. P.; Huang, L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 1990, 268, 235-7.
61. O'Shaughnessy, J. A. Pegylated liposomal doxorubicin in the treatment of breast cancer. Clin. Breast Cancer 2003, 4, 318-28.
62. Torchilin, V. P.; Omelyanenko, V. G; Papisov, M. I.; Bogdanov, A. A, Jr.; Trubetskoy, V. S.; Herron, J. N.; Gentry, C. A. Poly (ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity. Biochim. Biophys. Acta 1994, 1195, 11-20.
63. Seo, J. W.; Zhang, H; Kukis, D. L.; Meares, C. F.; Ferrara, K W. A novel method to label preformed liposomes with Cu for positron emission tomography (PET) imaging. Bioconjugate Chem. 2008, 19, 2577-84.
64. Seo, J. W.; Mahakian, L. M.; Kheirolomoom, A.; Zhang, H; Meares, C. F.; Ferdani, R; Anderson, C. J.; Ferrara, K W. Liposomal Cu-64 labeling method using bifunctional chelators: poly (ethylene glycol) spacer and chelator effects. Bioconjugate Chem. 2010, 21, 1206-15.
65. Seo, J. W.; Qin, S.; Mahakian, L. M.; Watson, K D.; Kheirolomoom, A.; Ferrara, K W. Positron emission tomography imaging of the stability of Cu-64 labeled dipalmitoyl and distearoyl lipids in liposomes. J. Controlled Release 2011, 151, 28-34.
66. Petersen, A. L.; Binderup, T.; Rasmussen, P.; Henriksen, J. R; Elema, D. R; Kjaer, A.; Andresen, T. L. Cu loaded liposomes as positron emission tomography imaging agents. Biomaterials 2011, 32, 2334-41.
67. 64Cu-TATE-liposomes in a human neuroendocrine carcinoma mouse model. J. Controlled Release 2012, 160, 254-63.
68. Sowa-Staszczak, A.; Hubalewska-Dydejczyk, A.; Tomaszuk, M. PRRT as neoadjuvant treatment in NET. Recent Results Cancer Res. 2013, 194, 479-85.
69. Allavena, P.; Sica, A.; Solinas, G.; Porta, C.; Mantovani, A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev. Oncol. Hematol. 2008, 66, 1-9.
70. Fukuda, K.; Kobayashi, A.; Watabe, K. The role of tumorassociated macrophage in tumor progression. Front. Biosci., Scholar Ed. 2012, 4, 787-98.
71. 64Cu liposomes. Biomaterials 2012, 33, 7785-93.
72. 18F]-radiolabeling preformed liposomes and determination of liposomal trafficking by positron emission tomography. J. Med. Chem. 2007, 50, 6454-7.
73. Urakami, T.; Kawaguchi, A. T.; Akai, S.; Hatanaka, K.; Koide, H.; Shimizu, K.; Asai, T.; Fukumoto, D.; Harada, N.; Tsukada, H.; Oku, N. In vivo distribution of liposome-encapsulated hemoglobin determined by positron emission tomography. Artif. Organs 2009, 33, 164-8.
74. 18F]FDP). Nucl. Med. Biol. 2007, 34, 165-71.
75. Paoli, E. E.; Kruse, D. E.; Seo, J. W.; Zhang, H.; Kheirolomoom, A.; Watson, K. D.; Chiu, P.; Stahlberg, H.; Ferrara, K. W. An optical and microPET assessment of thermally-sensitive liposome biodistribution in the Met-1 tumor model: Importance of formulation. J. Controlled Release 2010, 143, 13-22.
76. Oku, N.; Yamashita, M.; Katayama, Y.; Urakami, T.; Hatanaka, K.; Shimizu, K.; Asai, T.; Tsukada, H.; Akai, S.; Kanazawa, H. PET imaging of brain cancer with positron emitter-labeled liposomes. Int. J. Pharm. 2011, 403, 170-7.
77. Mitchell, N.; Kalber, T. L.; Cooper, M. S.; Sunassee, K.; Chalker, S. L.; Shaw, K. P.; Ordidge, K. L.; Badar, A.; Janes, S. M.; Blower, P. J.; Lythgoe, M. F.; Hailes, H. C.; Tabor, A. B. Incorporation of paramagnetic, fluorescent and PET/SPECT contrast agents into liposomes for multimodal imaging. Biomaterials 2013, 34, 1179-92.
78. Lavasanifar, A.; Samuel, J.; Kwon, G. S. Poly (ethylene oxide) - block-poly (L-amino acid) micelles for drug delivery. Adv. Drug Delivery Rev. 2002, 54, 169-90.
79. Wei, T.; Liu, J.; Ma, H.; Cheng, Q.; Huang, Y.; Zhao, J.; Huo, S.; Xue, X.; Liang, Z.; Liang, X. J. Functionalized nanoscale micelles improve drug delivery for cancer therapy in vitro and in vivo. Nano Lett. 2013, 13, 2528-34.
80. Kedar, U.; Phutane, P.; Shidhaye, S.; Kadam, V. Advances in polymeric micelles for drug delivery and tumor targeting. Nanomedicine 2010, 6, 714-29.
81. Mackiewicz, N.; Gravel, E.; Garofalakis, A.; Ogier, J.; John, J.; Dupont, D. M.; Gombert, K.; Tavitian, B.; Doris, E.; Duconge, F. Tumor-targeted polydiacetylene micelles for in vivo imaging and drug delivery. Small 2011, 7, 2786-92.
82. Cho, H.; Lai, T. C.; Kwon, G. S. Poly (ethylene glycol)-blockpoly (epsilon-caprolactone) micelles for combination drug delivery: evaluation of paclitaxel, cyclopamine and gossypol in intraperitoneal xenograft models of ovarian cancer. J. Controlled Release 2013, 166, 1-9.
83. Morris, P. G.; Abrey, L. E. Novel targeted agents for plateletderived growth factor receptor and c-KIT in malignant gliomas. Target Oncol. 2010, 5, 193-200.
84. Benezra, M.; Hambardzumyan, D.; Penate-Medina, O.; Veach, D. R.; Pillarsetty, N.; Smith-Jones, P.; Phillips, E.; Ozawa, T.; Zanzonico, P. B.; Longo, V.; Holland, E. C.; Larson, S. M.; Bradbury, M. S. Fluorine-labeled dasatinib nanoformulations as targeted molecular imaging probes in a PDGFB-driven murine glioblastoma model. Neoplasia 2012, 14, 1132-43.
85. Oerlemans, C.; Bult, W.; Bos, M.; Storm, G.; Nijsen, J. F.; Hennink, W. E. Polymeric micelles in anticancer therapy: targeting, imaging and triggered release. Pharm. Res. 2010, 27, 2569-89.
86. Xiao, Y.; Hong, H.; Javadi, A.; Engle, J. W.; Xu, W.; Yang, Y.; Zhang, Y.; Barnhart, T. E.; Cai, W.; Gong, S. Multifunctional unimolecular micelles for cancer-targeted drug delivery and positron emission tomography imaging. Biomaterials 2012, 33, 3071-82.
87. Guo, J.; Hong, H.; Chen, G.; Shi, S.; Zheng, Q.; Zhang, Y.; Theuer, C. P.; Barnhart, T. E.; Cai, W.; Gong, S. Image-guided and tumor-targeted drug delivery with radiolabeled unimolecular micelles. Biomaterials 2013, 34, 8323-32.
88. Xu, G.; McLeod, H. L. Strategies for enzyme/prodrug cancer therapy. Clin. Cancer Res. 2001, 7, 3314-24.
89. Tong, X.; Chen, X.; Li, C. Imaging beyond the diagnosis: imageguided enzyme/prodrug cancer therapy. Acta Biochim. Biophys. Sin. (Shanghai) 2011, 43, 4-12.
90. Li, C.; Penet, M. F.; Winnard, P., Jr.; Artemov, D.; Bhujwalla, Z. M. Image-guided enzyme/prodrug cancer therapy. Clin. Cancer Res. 2008, 14, 515-22.
91. Springer, C. J.; Niculescu-Duvaz, I. I. Antibody-directed enzyme prodrug therapy (ADEPT): a review. Adv. Drug Delivery Rev. 1997, 26, 151-172.
92. Bagshawe, K. D.; Sharma, S. K.; Burke, P. J.; Melton, R. G.; Knox, R. J. Developments with targeted enzymes in cancer therapy. Curr. Opin. Immunol 1999, 11, 579-83.
93. Silva, A. T.; Chung, M. C.; Castro, L. F.; Guido, R. V.; Ferreira, E. I. Advances in prodrug design. Mini-Rev. Med. Chem. 2005, 5, 893-914.
94. Bhaumik, S. Advances in imaging gene-directed enzyme prodrug therapy. Curr. Pharm. Biotechnol. 2011, 12, 497-507.
95. Szabo, Z.; Xia, J.; Mathews, W. B.; Brown, P. R. Future direction of renal positron emission tomography. Semin. Nucl. Med. 2006, 36, 36-50.
96. Wunderbaldinger, P.; Bogdanov, A.; Weissleder, R. New approaches for imaging in gene therapy. Eur. J. Radiol. 2000, 34, 156-65.
97. Bankiewicz, K. S.; Eberling, J. L.; Kohutnicka, M.; Jagust, W.; Pivirotto, P.; Bringas, J.; Cunningham, J.; Budinger, T. F.; Harvey-White, J. Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp. Neurol. 2000, 164, 2-14.
98. Jacobs, A.; Voges, J.; Reszka, R.; Lercher, M.; Gossmann, A.; Kracht, L.; Kaestle, C.; Wagner, R.; Wienhard, K.; Heiss, W. D. Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas. Lancet 2001, 358, 727-9.
99. 124I]FIAU and PET. Mol. Imaging 2002, 1, 36-42.
100. Malik, N.; Luthra, S. K.; Burke, P.; Price, P. M.; Aboagye, E. O.; Latigo, J.; Zhao, Y.; Brady, F. Radiosynthesis of 4-[(2-chloroethyl) (2-[11C]ethyl) amino]-phenoxycarbonyl-l-glutamic acid a half mustard prodrug as a potential probe for imaging antibody- and gene-directed enzyme prodrug therapy with positron emission tomography. Appl. Radiat. Isot. 2004, 60, 825-834.
101. Eiseman, J. L.; Brown-Proctor, C.; Kinahan, P. E.; Collins, J. M.; Anderson, L. W.; Joseph, E.; Hamburger, D. R.; Pan, S. S.; Mathis, C. A.; Egorin, M. J.; Klecker, R. W. Distribution of 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) uracil in mice bearing colorectal cancer xenografts: rationale for therapeutic use and as a positron emission tomography probe for thymidylate synthase. Clin. Cancer Res. 2004, 10, 6669-76.
102. Tseng, J. C.; Zanzonico, P. B.; Levin, B.; Finn, R.; Larson, S. M.; Meruelo, D. Tumor-specific in vivo transfection with HSV-1 thymidine kinase gene using a Sindbis viral vector as a basis for prodrug ganciclovir activation and PET. J. Nucl. Med. 2006, 47, 1136-43.
103. Stelter, L.; Tseng, J. C.; Torosjan, A.; Levin, B.; Longo, V. A.; Pillarsetty, N.; Zanzonico, P.; Meruelo, D.; Larson, S. M. Tumorspecific targeting with modified Sindbis viral vectors: evaluation with optical imaging and positron emission tomography in vivo. Mol. Imaging Biol. 2013, 15, 166-74.
104. 18F-FDG for monitoring herpes simplex virus type 1 thymidine kinase and ganciclovir prodrug activation gene therapy of cancer. J. Nucl. Med. 2006, 47, 1161-71.
105. 18F]-FEAnGA as a PET Tracer for beta-glucuronidase activity. Bioconjugate Chem. 2010, 21, 911-20.
106. Antunes, I. F.; Haisma, H. J.; Elsinga, P. H.; van Waarde, A.; Willemsen, A. T.; Dierckx, R. A.; de Vries, E. F. In vivo evaluation of 1-O-(4-(2-fluoroethyl-carbamoyloxymethyl)-2-nitrophenyl)-O-beta-D-glucopyronurona te: a positron emission tomographic tracer for imaging beta-glucuronidase activity in a tumor/inflammation rodent model. Mol. Imaging 2012, 11, 77-87.
107. Antunes, I. F.; Haisma, H. J.; Elsinga, P. H.; Di Gialleonardo, V.; van Waarde, A.; Willemsen, A. T.; Dierckx, R. A.; de Vries, E. F. Induction of beta-glucuronidase release by cytostatic agents in small tumors. Mol. Pharmaceutics 2012, 9, 3277-85.
108. Moon, B. S.; Jang, S. J.; Kim, S. J.; Lee, T. S.; Chi, D. Y.; Lee, B. C.; Kang, J. H.; Kim, S. E. Synthesis and evaluation of a 18F-labeled 4-ipomeanol as an imaging agent for CYP4B1 gene prodrug activation therapy. Cancer Biother. Radiopharm. 2013, 28, 588-97.
109. Zhu, Q.; Talton, J.; Zhang, G.; Cunningham, T.; Wang, Z.; Waters, R. C.; Kirk, J.; Eppler, B.; Klinman, D. M.; Sui, Y.; Gagnon, S.; Belyakov, I. M.; Mumper, R. J.; Berzofsky, J. A. Large intestinetargeted, nanoparticle-releasing oral vaccine to control genitorectal viral infection. Nat. Med. 2012, 18, 1291-6.
110. Kochut, A.; Dersch, P. Bacterial invasion factors: tools for crossing biological barriers and drug delivery? Eur. J. Pharm. Biopharm. 2013, 84, 242-50.
111. Zhao, Y.; Trewyn, B. G.; Slowing, I. I.; Lin, V. S. Mesoporous silica nanoparticle-based double drug delivery system for glucoseresponsive controlled release of insulin and cyclic AMP. J. Am. Chem. Soc. 2009, 131, 8398-400.
112. Patil, Y. B.; Swaminathan, S. K.; Sadhukha, T.; Ma, L.; Panyam, J. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials 2010, 31, 358-65.
113. Fang, W.; Yang, J.; Gong, J.; Zheng, N. Photo- and pH-Triggered Release of Anticancer Drugs from Mesoporous Silica-Coated Pd@Ag Nanoparticles. Adv. Funct Mater. 2012, 22, 842-848.
114. Klichko, Y.; Liong, M.; Choi, E.; Angelos, S.; Nel, A. E.; Stoddart, J. F.; Tamanoi, F.; Zink, J. I. Mesostructured Silica for Optical Functionality, Nanomachines, and Drug Delivery. J. Am. Ceram. Soc. 2009, 92, s2-s10.
115. Kim, J. H.; Noh, Y. W.; Heo, M. B.; Cho, M. Y.; Lim, Y. T. Multifunctional hybrid nanoconjugates for efficient in vivo delivery of immunomodulating oligonucleotides and enhanced antitumor immunity. Angew. Chem., Int. Ed. 2012, 51, 9670-3.
116. Bagalkot, V.; Gao, X. siRNA-aptamer chimeras on nanoparticles: preserving targeting functionality for effective gene silencing. ACS Nano 2011, 5, 8131-9.
117. Sardesai, N. P.; Barron, J. C.; Rusling, J. F. Carbon nanotube microwell array for sensitive electrochemiluminescent detection of cancer biomarker proteins. Anal. Chem. 2011, 83, 6698-703.
118. Chen, T.; Shukoor, M. I.; Wang, R.; Zhao, Z.; Yuan, Q.; Bamrungsap, S.; Xiong, X.; Tan, W. Smart multifunctional nanostructure for targeted cancer chemotherapy and magnetic resonance imaging. ACS Nano 2011, 5, 7866-73.
119. Gao, Y.; Yang, C.; Liu, X.; Ma, R.; Kong, D.; Shi, L. A multifunctional nanocarrier based on nanogated mesoporous silica for enhanced tumor-specific uptake and intracellular delivery. Macromol. Biosci. 2012, 12, 251-9.
120. Xia, T.; Kovochich, M.; Liong, M.; Meng, H.; Kabehie, S.; George, S.; Zink, J. I.; Nel, A. E. Polyethyleneimine coating enhances the cellular uptake of mesoporous silica nanoparticles and allows safe delivery of siRNA and DNA constructs. ACS Nano 2009, 3, 3273-86.
121. Li, J.; Gupta, S.; Li, C. Research perspectives: gold nanoparticles in cancer theranostics. Quant. Imaging Med. Surg. 2013, 3, 284-91.
122. Liboiron, B. D.; Mayer, L. D. Nanoscale particulate systems for multidrug delivery: towards improved combination chemotherapy. Ther. Delivery 2014, 5, 149-71.
123. Sanchez-Dominguez, C. N.; Gallardo-Blanco, H. L.; Rodriguez-Rodriguez, A. A.; Vela-Gonzalez, A. V.; Sanchez-Dominguez, M. Nanoparticles vs cancer: a multifuncional tool. Curr. Top. Med. Chem. 2014, 14, 664-75.
124. Long, N. V.; Thi, C. M.; Yong, Y.; Cao, Y.; Nogami, M. Synthesis and Characterization of Fe-Based Metal and Oxide Based Nanoparticles: Discoveries and Research Highlights of Potential Applications in Biology and Medicine. Recent Pat. Nanotechnol. 2014, 8, 52-61.
125. Lepeltier, E.; Bourgaux, C.; Couvreur, P. Nanoprecipitation and the "Ouzo effect": Application to drug delivery devices. Adv. Drug Delivery Rev. 2014, 71, 86-97, DOI: 10.1016/j.addr.2013.12.009.
126. Bhattacharya, R.; Mukherjee, P.; Xiong, Z.; Atala, A.; Soker, S.; Mukhopadhyay, D. Gold Nanoparticles Inhibit VEGF165-Induced Proliferation of HUVEC Cells. Nano Lett. 2004, 4, 2479-81.
127. Kogan, M. J.; Olmedo, I.; Hosta, L.; Guerrero, A. R.; Cruz, L. J.; Albericio, F. Peptides and metallic nanoparticles for biomedical applications. Nanomedicine (London) 2007, 2, 287-306.
128. Hosta-Rigau, L.; Olmedo, I.; Arbiol, J.; Cruz, L. J.; Kogan, M. J.; Albericio, F. Multifunctionalized gold nanoparticles with peptides targeted to gastrin-releasing peptide receptor of a tumor cell line. Bioconjugate Chem. 2010, 21, 1070-8.
129. Hosta, L.; Pla-Roca, M.; Arbiol, J.; Lopez-Iglesias, C.; Samitier, J.; Cruz, L. J.; Kogan, M. J.; Albericio, F. Conjugation of Kahalalide F with gold nanoparticles to enhance in vitro antitumoral activity. Bioconjugate Chem. 2009, 20, 138-46.
130. 18F-labeled conjugate goldnanoparticle-peptide with potential biomedical application. Bioconjugate Chem. 2012, 23, 399-408.
131. Kuo, W. S.; Chang, C. N.; Chang, Y. T.; Yang, M. H.; Chien, Y. H.; Chen, S. J.; Yeh, C. S. Gold nanorods in photodynamic therapy, as hyperthermia agents, and in near-infrared optical imaging. Angew. Chem., Int. Ed. 2010, 49, 2711-5.
132. Xiao, Y.; Hong, H.; Matson, V. Z.; Javadi, A.; Xu, W.; Yang, Y.; Zhang, Y.; Engle, J. W.; Nickles, R. J.; Cai, W.; Steeber, D. A.; Gong, S. Gold Nanorods Conjugated with Doxorubicin and cRGD for Combined Anticancer Drug Delivery and PET Imaging. Theranostics 2012, 2, 757-68.
133. 3targeted gold nanoshells augment tumor vasculature-specific imaging and therapy. Int. J. Nanomedicine 2011, 6, 259-69.
134. Kwon, S.; Singh, R. K.; Perez, R. A.; Abou Neel, E. A.; Kim, H. W.; Chrzanowski, W. Silica-based mesoporous nanoparticles for controlled drug delivery. J. Tissue Eng. 2013, DOI: 10.1177/2041731413503357.
135. Turcheniuk, K.; Tarasevych, A. V.; Kukhar, V. P.; Boukherroub, R.; Szunerits, S. Recent advances in surface chemistry strategies for the fabrication of functional iron oxide based magnetic nanoparticles. Nanoscale 2013, 5, 10729-52.
136. Benezra, M.; Penate-Medina, O.; Zanzonico, P. B.; Schaer, D.; Ow, H.; Burns, A.; DeStanchina, E.; Longo, V.; Herz, E.; Iyer, S.; Wolchok, J.; Larson, S. M.; Wiesner, U.; Bradbury, M. S. Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. J. Clin. Invest. 2011, 121, 2768-80.
137. Burns, A. A.; Vider, J.; Ow, H.; Herz, E.; Penate-Medina, O.; Baumgart, M.; Larson, S. M.; Wiesner, U.; Bradbury, M. Fluorescent silica nanoparticles with efficient urinary excretion for nanomedicine. Nano Lett. 2009, 9, 442-8.
138. US FDA. Investigational New Drug approval for first-in-human trial of novel cancer-targeting nanoparticle. News & Analysis. Ther. Delivery 2011, 2, 287.
139. Tang, L.; Yang, X.; Dobrucki, L. W.; Chaudhury, I.; Yin, Q.; Yao, C.; Lezmi, S.; Helferich, W. G.; Fan, T. M.; Cheng, J. Aptamerfunctionalized, ultra-small, monodisperse silica nanoconjugates for targeted dual-modal imaging of lymph nodes with metastatic tumors. Angew. Chem., Int. Ed. 2012, 51, 12721-6.
140. Kim, J. S.; Kim, Y. H.; Kim, J. H.; Kang, K. W.; Tae, E. L.; Youn, H.; Kim, D.; Kim, S. K.; Kwon, J. T.; Cho, M. H.; Lee, Y. S.; Jeong, J. M.; Chung, J. K.; Lee, D. S. Development and in vivo imaging of a PET/MRI nanoprobe with enhanced NIR fluorescence by dye encapsulation. Nanomedicine (London) 2012, 7, 219-29.
141. Di Pasqua, A. J.; Yuan, H.; Chung, Y.; Kim, J. K.; Huckle, J. E.; Li, C.; Sadgrove, M.; Tran, T. H.; Jay, M.; Lu, X. Neutron-activatable holmium-containing mesoporous silica nanoparticles as a potential radionuclide therapeutic agent for ovarian cancer. J. Nucl. Med. 2013, 54, 111-6.
142. Chen, F.; Hong, H.; Zhang, Y.; Valdovinos, H. F.; Shi, S.; Kwon, G. S.; Theuer, C. P.; Barnhart, T. E.; Cai, W. In vivo tumor targeting and image-guided drug delivery with antibody-conjugated, radiolabeled mesoporous silica nanoparticles. ACS Nano 2013, 7, 9027-39.
143. Choi, J. S.; Park, J. C.; Nah, H.; Woo, S.; Oh, J.; Kim, K. M.; Cheon, G. J.; Chang, Y.; Yoo, J.; Cheon, J. A hybrid nanoparticle probe for dual-modality positron emission tomography and magnetic resonance imaging. Angew. Chem., Int. Ed. 2008, 47, 6259-62.
144. 4 dumbbell nanoparticles as dual-functional probes. Angew. Chem., Int. Ed. 2008, 47, 173-6.
145. Lee, S.; Chen, X. Dual-modality probes for in vivo molecular imaging. Mol. Imaging 2009, 8, 87-100.
146. Xie, J.; Huang, J.; Li, X.; Sun, S.; Chen, X. Iron oxide nanoparticle platform for biomedical applications. Curr. Med. Chem. 2009, 16, 1278-94.
147. Xie, J.; Chen, K.; Huang, J.; Lee, S.; Wang, J.; Gao, J.; Li, X.; Chen, X. PET/NIRF/MRI triple functional iron oxide nanoparticles. Biomaterials 2010, 31, 3016-22.
148. Chen, F.; Ellison, P. A.; Lewis, C. M.; Hong, H.; Zhang, Y.; Shi, S.; Hernandez, R.; Meyerand, M. E.; Barnhart, T. E.; Cai, W. Chelatorfree synthesis of a dual-modality PET/MRI agent. Angew. Chem., Int. Ed. 2013, 52, 13319-23.
149. 77As from Ge for Biomedical Applications. Chromatographia 2011, 74, 531-540.
150. Yang, X.; Hong, H.; Grailer, J. J.; Rowland, I. J.; Javadi, A.; Hurley, S. A.; Xiao, Y.; Yang, Y.; Zhang, Y.; Nickles, R. J.; Cai, W.; Steeber, D. A.; Gong, S. cRGD-functionalized, DOX-conjugated, and 64Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging. Biomaterials 2011, 32, 4151-60.
151. Peer, D.; Karp, J. M.; Hong, S.; Farokhzad, O. C.; Margalit, R.; Langer, R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007, 2, 751-60.
152. Bartlett, D. W.; Su, H.; Hildebrandt, I. J.; Weber, W. A.; Davis, M. E. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 15549-54.
153. 64Cu-labeled polymer nanoparticles targeted to the lung endothelium. J. Nucl. Med. 2008, 49, 103-11.
154. Simone, E. A.; Zern, B. J.; Chacko, A. M.; Mikitsh, J. L.; Blankemeyer, E. R.; Muro, S.; Stan, R. V.; Muzykantov, V. R. Endothelial targeting of polymeric nanoparticles stably labeled with the PET imaging radioisotope iodine-124. Biomaterials 2012, 33, 5406-13.
155. Zhu, Z.; Li, Y.; Li, X.; Li, R.; Jia, Z.; Liu, B.; Guo, W.; Wu, W.; Jiang, X. Paclitaxel-loaded poly (N-vinylpyrrolidone)-b-poly (epsiloncaprolactone) nanoparticles: preparation and antitumor activity in vivo. J. Controlled Release 2010, 142, 438-46.
156. Liu, Q.; Li, R.; Zhu, Z.; Qian, X.; Guan, W.; Yu, L.; Yang, M.; Jiang, X.; Liu, B. Enhanced antitumor efficacy, biodistribution and penetration of docetaxel-loaded biodegradable nanoparticles. Int. J. Pharm. 2012, 430, 350-8.
157. Zhou, J.; Patel, T. R.; Sirianni, R. W.; Strohbehn, G.; Zheng, M. Q.; Duong, N.; Schafbauer, T.; Huttner, A. J.; Huang, Y.; Carson, R. E.; Zhang, Y.; Sullivan, D. J., Jr.; Piepmeier, J. M.; Saltzman, W. M. Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma. Proc. Natl. Acad. Sci. U. S. A. 2013, 110, 11751-6.
158. Chen, K. J.; Tang, L.; Garcia, M. A.; Wang, H.; Lu, H.; Lin, W. Y.; Hou, S.; Yin, Q.; Shen, C. K.; Cheng, J.; Tseng, H. R. The therapeutic efficacy of camptothecin-encapsulated supramolecular nanoparticles. Biomaterials 2012, 33, 1162-9.
159. Jeong, B.; Bae, Y. H.; Lee, D. S.; Kim, S. W. Biodegradable block copolymers as injectable drug-delivery systems. Nature 1997, 388, 860-2.
160. Fukukawa, K.; Rossin, R.; Hagooly, A.; Pressly, E. D.; Hunt, J. N.; Messmore, B. W.; Wooley, K. L.; Welch, M. J.; Hawker, C. J. Synthesis and characterization of core-shell star copolymers for in vivo PET imaging applications. Biomacromolecules 2008, 9, 1329-39.
161. 64Cu copolymer targeting tumor angiogenesis: tumor localization visualized by positron emission tomography. Mol. Imaging 2013, 12, 203-12.
162. Cha, C.; Shin, S. R.; Annabi, N.; Dokmeci, M. R.; Khademhosseini, A. Carbon-based nanomaterials: multifunctional materials for biomedical engineering. ACS Nano 2013, 7, 2891-7.
163. Iijima, S.; Ichihashi, T. Single-shell carbon nanotubes of 1-nm diameter. Nature 1993, 363, 603-5.
164. Gong, H.; Peng, R.; Liu, Z. Carbon nanotubes for biomedical imaging: the recent advances. Adv. Drug Delivery Rev. 2013, 65, 1951-63.
165. Liu, Z.; Cai, W.; He, L.; Nakayama, N.; Chen, K.; Sun, X.; Chen, X.; Dai, H. In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat. Nanotechnol. 2007, 2, 47-52.
166. McDevitt, M. R.; Chattopadhyay, D.; Jaggi, J. S.; Finn, R. D.; Zanzonico, P. B.; Villa, C.; Rey, D.; Mendenhall, J.; Batt, C. A.; Njardarson, J. T.; Scheinberg, D. A. PET imaging of soluble yttrium-86-labeled carbon nanotubes in mice. PLoS One 2007, 2, e907.
167. Hong, H.; Yang, K.; Zhang, Y.; Engle, J. W.; Feng, L.; Yang, Y.; Nayak, T. R.; Goel, S.; Bean, J.; Theuer, C. P.; Barnhart, T. E.; Liu, Z.; Cai, W. In vivo targeting and imaging of tumor vasculature with radiolabeled, antibody-conjugated nanographene. ACS Nano 2012, 6, 2361-70.
168. 66Ga-labeled nano-graphene. Biomaterials 2012, 33, 4147-56.
169. Shi, S.; Yang, K.; Hong, H.; Valdovinos, H. F.; Nayak, T. R.; Zhang, Y.; Theuer, C. P.; Barnhart, T. E.; Liu, Z.; Cai, W. Tumor vasculature targeting and imaging in living mice with reduced graphene oxide. Biomaterials 2013, 34, 3002-9.
170. Robinson, J. T.; Tabakman, S. M.; Liang, Y.; Wang, H.; Casalongue, H. S.; Vinh, D.; Dai, H. Ultrasmall reduced graphene oxide with high near-infrared absorbance for photothermal therapy. J. Am. Chem. Soc. 2011, 133, 6825-31.
171. Del Vecchio, S.; Zannetti, A.; Fonti, R.; Pace, L.; Salvatore, M. Nuclear imaging in cancer theranostics. Q. J. Nucl. Med. Mol. Imaging 2007, 51, 152-63.
172. Baum, R. P.; Kulkarni, H. R. THERANOSTICS: From Molecular Imaging Using Ga-68 Labeled Tracers and PET/CT to Personalized Radionuclide Therapy - The Bad Berka Experience. Theranostics 2012, 2, 437-47.
173. Oberg, K. Molecular Imaging Radiotherapy: Theranostics for Personalized Patient Management of Neuroendocrine Tumors (NETs). Theranostics 2012, 2, 448-58.
174. Velikyan, I. Molecular imaging and radiotherapy: theranostics for personalized patient management. Theranostics 2012, 2, 424-6.
175. 18F-FDG PET and PET/CT in the evaluation of cancer treatment response. J. Nucl. Med. 2009, 50, 88-99.
176. Hess, S.; Blomberg, B. A.; Zhu, H. J.; Hoilund-Carlsen, P. F.; Alavi, A. The Pivotal Role of FDG-PET/CT in Modern Medicine. Acad. Radiol. 2014, 21, 232-49.
177. 18F]FDG for use in oncology and neurosciences. Nucl. Med. Biol. 2010, 37, 727-40.
178. Cole, E. L.; Stewart, M. N.; Littich, R.; Hoareau, R.; Scott, P. J. Radiosyntheses Using Fluorine-18: the Art and Science of Late Stage Fluorination. Curr. Top. Med. Chem. 2014, 14, 875-900.
179. Groheux, D.; Espie, M.; Giacchetti, S.; Hindie, E. Performance of FDG PET/CT in the clinical management of breast cancer. Radiology 2013, 266, 388-405.
180. Li, D.; Lu, P. X. Application of fluorine-18 fluorodeoxyglucosepositron emission tomography and positron emission tomography computed tomography in patients with tuberculosis. Zhonghua Jiehe He Huxi Zazhi 2012, 35, 852-4.
181. 18F-based radiotracers. Am. J. Nucl. Med. Mol. Imaging 2012, 2, 55-76.
182. Caldarella, C.; Isgro, M. A.; Treglia, I.; Treglia, G. Is fluorine-18-fluorodeoxyglucose positron emission tomography useful in monitoring the response to treatment in patients with multiple myeloma? Int. J. Hematol. 2012, 96, 685-91.
183. Morgat, C.; Hindie, E.; Mishra, A. K.; Allard, M.; Fernandez, P. Gallium-68: chemistry and radiolabeled peptides exploring different oncogenic pathways. Cancer Biother. Radiopharm. 2013, 28, 85-97.
184. 68Ga generators. Appl. Radiat. Isot. 2013, 76, 24-30.
185. 68Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives. Semin. Nucl. Med. 2011, 41, 314-21.
186. Banerjee, S. R.; Pomper, M. G. Clinical applications of Gallium-68. Appl. Radiat. Isot. 2013, 76, 2-13.
187. Basu, S.; Kumar, R.; Rubello, D.; Fanti, S.; Alavi, A. PET imaging in neuroendocrine tumors: current status and future prospects. Minerva Endocrinol. 2008, 33, 257-75.
188. Kaemmerer, D.; Prasad, V.; Daffner, W.; Haugvik, S. P.; Senftleben, S.; Baum, R. P.; Hommann, M. Radioguided surgery in neuroendocrine tumors using Ga-68-labeled somatostatin analogs: a pilot study. Clin. Nucl. Med. 2012, 37, 142-7.
189. Win, Z.; Al-Nahhas, A.; Rubello, D.; Gross, M. D. Somatostatin receptor PET imaging with Gallium-68 labeled peptides. Q. J. Nucl. Med. Mol. Imaging 2007, 51, 244-50.
190. 177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma. J. Nucl. Med. 2011, 52, 1041-7.
191. 177Lutetium labeled somatostatin analogs: toxicity, response and survival analysis. Am. J. Nucl. Med. Mol. Imaging 2013, 4, 39-52.
192. 90Y-SIR spheres: radiobiologic considerations. J. Nucl. Med. 2010, 51, 1377-85.
193. 90Y-SIR-Spheres. J. Nucl. Med. 2010, 51(S2), 1553.
194. 90Y SIR-Spheres: a radiolabeling and stability study. Nucl. Med. Biol. 2007, 34, 585-90.
195. Capala, J.; Bouchelouche, K. Molecular imaging of HER2-positive breast cancer: a step toward an individualized 'image and treat' strategy. Curr. Opin. Oncol. 2010, 22, 559-66.
196. Jacob, J.; Kirova, Y. M. Locoregional breast radiotherapy and concurrent treatment with trastuzumab. Bull. Cancer 2014, 101, 40-51.
197. Stipsanelli, E.; Valsamaki, P. Monoclonal antibodies: old and new trends in breast cancer imaging and therapeutic approach. Hell J. Nucl. Med. 2005, 8, 103-8.
198. 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin. Pharmacol. Ther. 2010, 87, 586-92.
199. Bourgeois, A. C.; Chang, T. T.; Fish, L. M.; Bradley, Y. C. Positron emission tomography/computed tomography in melanoma. Radiol. Clin. North Am. 2013, 51, 865-79.
200. Brunetti, J. PET/CT in gynecologic malignancies. Radiol. Clin. North Am. 2013, 51, 895-911.
201. Bunevicius, A.; Yuan, H.; Lin, W. The potential roles of 18F-FDG-PET in management of acute stroke patients. Biomed. Res. Int. 2013, DOI: 10.1155/2013/634598.
202. Elsinga, P. H.; Dierckx, R. A. Small Molecule PET-Radiopharmaceuticals. Curr. Pharm. Des 2014, 20, 2268-74.
203. Escott, E. J. Role of positron emission tomography/computed tomography (PET/CT) in head and neck cancer. Radiol. Clin. North Am. 2013, 51, 881-93.
204. 89Zr, a radiometal nuclide with high potential for molecular imaging with PET: chemistry, applications and remaining challenges. Molecules 2013, 18, 6469-90.
205. Fularz, M.; Adamiak, P.; Czepczynski, R.; Jarzabek-Bielecka, G.; Kedzia, W.; Ruchala, M. Positron emission tomography (PET) in malignant ovarian tumors. Ginekol. Pol. 2013, 84, 720-5.
206. Hinds, S. R., 2nd; Stocker, D. J.; Bradley, Y. C. Role of positron emission tomography/computed tomography in dementia. Radiol. Clin. North Am. 2013, 51, 927-34.
207. Jadvar, H. Molecular imaging of prostate cancer with PET. J. Nucl. Med. 2013, 54, 1685-8.
208. Lecouvet, F. E.; Lhommel, R.; Pasoglou, V.; Larbi, A.; Jamar, F.; Tombal, B. Novel imaging techniques reshape the landscape in high-risk prostate cancers. Curr. Opin. Urol. 2013, 23, 323-30.
209. Mirpour, S.; Mhlanga, J. C.; Logeswaran, P.; Russo, G.; Mercier, G.; Subramaniam, R. M. The role of PET/CT in the management of cervical cancer. AJR, Am. J. Roentgenol 2013, 201, W192-205.
210. Nemeth, Z.; Boer, K.; Kasler, M.; Borbely, K. Clinical use of 18F-FDG PET/CT in colorectal carcinoma. Orv. Hetil. 2013, 154, 1447-53.
211. 18F-FDG PET/CT in staging and restaging cholangiocarcinoma. Recenti Prog. Med. 2013, 104, 328-35.
212. Ouvrier, M. J.; Vignot, S.; Thariat, J. State of the art in nuclear imaging for the diagnosis of bone metastases. Bull. Cancer 2013, 100, 1115-24.
213. Shreve, P.; Faasse, T. Role of positron emission tomographycomputed tomography in pulmonary neoplasms. Radiol. Clin. North Am. 2013, 51, 767-79.
214. Velikyan, I. Prospective of Ga-Radiopharmaceutical Development. Theranostics 2013, 4, 47-80.
215. Viswanathan, C.; Bhosale, P. R.; Shah, S. N.; Vikram, R. Positron emission tomography-computed tomography imaging for malignancies in women. Radiol. Clin. North Am. 2013, 51, 1111-25.
216. Wang, L.; Tang, K.; Zhang, Q.; Li, H.; Wen, Z.; Zhang, H.; Zhang, H. Somatostatin receptor-based molecular imaging and therapy for neuroendocrine tumors. Biomed. Res. Int. 2013, 2013, 102819.
217. Wright, B. D.; Lapi, S. E. Designing the magic bullet? The advancement of immuno-PET into clinical use. J. Nucl. Med. 2013, 54, 1171-4.
218. Holland, J. P.; Williamson, M. J.; Lewis, J. S. Unconventional nuclides for radiopharmaceuticals. Mol. Imaging 2010, 9, 1-20.
219. 86Y. Curr. Radiopharm. 2011, 4, 122-30.
220. Bourgeois, M.; Rajerison, H.; Guerard, F.; Mougin-Degraef, M.; Barbet, J.; Michel, N.; Cherel, M.; Faivre-Chauvet, A. Contribution of [64Cu]-ATSM PET in molecular imaging of tumour hypoxia compared to classical [18F]-MISO-a selected review. Nucl. Med. Rev. Cent. East. Eur. 2011, 14, 90-5.
221. Vavere, A. L.; Rossin, R. Molecular imaging of cancer with radiolabeled peptides and PET. Anticancer Agents Med. Chem. 2012, 12, 462-75.
222. Welch, M. J.; Laforest, R.; Lewis, J. S. Production of nonstandard PET radionuclides and the application of radiopharmaceuticals labeled with these nuclides. Ernst Schering Res. Found. Workshop 2007, 159-81.
223. 89Zr: from radiochemistry to the clinic. Nucl. Med. Biol. 2013, 40, 3-14.
224. Urruticoechea, A.; Alemany, R.; Balart, J.; Villanueva, A.; Vinals, F. Capella, G. Recent advances in cancer therapy: an overview. Curr. Pharm. Des. 2010, 16, 3-10.
225. Riehemann, K.; Schneider, S. W.; Luger, T. A.; Godin, B.; Ferrari, M.; Fuchs, H. Nanomedicine-challenge and perspectives. Angew. Chem., Int. Ed. 2009, 48, 872-97.
226. Sanhai, W. R.; Sakamoto, J. H.; Canady, R.; Ferrari, M. Seven challenges for nanomedicine. Nat. Nanotechnol. 2008, 3, 242-4.
227. Lanza, G. M.; Moonen, C.; Baker, J. R., Jr.; Chang, E.; Cheng, Z.; Grodzinski, P.; Ferrara, K.; Hynynen, K.; Kelloff, G.; Lee, Y. E.; Patri, A. K.; Sept, D.; Schnitzer, J. E.; Wood, B. J.; Zhang, M.; Zheng, G.; Farahani, K. Assessing the barriers to image-guided drug delivery. Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol. 2014, 6, 1-14.